Markets:

Overview

News

Currencies

International

Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.235 +0.085 (+2.05%)

Streaming Delayed Price Updated: 9:31 AM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth ↗

December 13, 2023

Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside.

Via InvestorPlace

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

December 13, 2023

From Verastem Oncology

Via Business Wire

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential ↗

December 03, 2023

Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.

Via InvestorPlace

Where Verastem Stands With Analysts ↗

November 15, 2023

Via Benzinga

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

November 13, 2023

From Verastem Oncology

Via Business Wire

Analyst Ratings for Verastem ↗

September 27, 2023

Via Benzinga

Truist Securities Maintains Buy Rating for Verastem: Here's What You Need To Know ↗

July 11, 2023

Via Benzinga

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 08, 2023

From Verastem Oncology

Via Business Wire

First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer

November 07, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

November 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

October 26, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 18, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

October 14, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 06, 2023

From Verastem Oncology

Via Business Wire

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

September 28, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in Upcoming Investor Conferences

September 05, 2023

From Verastem Oncology

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023 ↗

September 27, 2023

Via Benzinga

3 Penny Stocks That Can Triple Your Money in the Next 12 Months ↗

September 04, 2023

Although penny stocks are among the most speculative asset classes, these wagers just happen to have strong analyst backing.

Via InvestorPlace

Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal ↗

September 02, 2023

Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet...

Via Talk Markets

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

August 28, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 08, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

July 11, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

July 05, 2023

From Verastem Oncology

Via Business Wire

Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket ↗

June 16, 2023

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use...

Via Benzinga

Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants

June 16, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 15, 2023

From Verastem Oncology

Via Business Wire

Crude Oil Rises Sharply; Jabil Posts Upbeat Q3 Results ↗

June 15, 2023

U.S. stocks traded higher toward the end of trading, with Dow Jones gaining around 450 points on Thursday. The Dow traded up 1.32% to 34,429.39 while the NASDAQ rose 1.27% to 13,799.28. The S&P 500,...

Via Benzinga

Verastem's Ovarian Cancer Drug Showing Promise, Analyst Upgrades Stock ↗

June 15, 2023

Mizuho Securities has upgraded Verastem Inc (NASDAQ: VSTM) from Neutral to Buy with a price target of $36, up from $24, to

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 15, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.